Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Sciences' '05 Losses Widen 3.7 Percent on Shriveled Sales

This update serves to correct the reported net loss and clarify Proteome Sciences' expectation that protein biomarkers may be used to accelerate drug development and reduce costs.
 
NEW YORK (GenomeWeb News) - Proteome Sciences said full-year 2005 net losses increased 3.7 percent to £4.17 million ($7.7 million) from £4.02 million year over year.
 
The preliminary year-end report, released yesterday, also showed that total revenue slumped more than 77 percent to £16,200 from £73,000 a year ago.
 
Explaining the slump, Proteome Sciences CEO Christopher Pearce said adoption of protein-related technology was slower than expected and some deals scheduled to close at year-end were delayed.
 
However, the company has seen a significant increase in the number of pharmaceutical companies that have approached it during the first half of 2006.
 
Proteome Sciences said it expects protein biomarkers to accelerate drug development and reduce costs, and said its highest priority is to expand its licensing program to other companies.
 
The company had cash and equivalents of £2.6 million at year's end.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.